<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="typing of human rhinovirus of adults hospitalized for exacerbation of" exact="asthma" post="and chronic obstructive pulmonary disease KoFanny Wai-san1ChanPaul Kay-sheung2ChanRenee W."/>
 <result pre="human rhinovirus of adults hospitalized for exacerbation of asthma and" exact="chronic obstructive pulmonary disease" post="KoFanny Wai-san1ChanPaul Kay-sheung2ChanRenee W. Y.3ChanKa-Pang1IpApril1KwokAngela2NgaiJenny Chun-li1NgSo-Shan1OnChan Tat1http://orcid.org/0000-0003-4382-2445HuiDavid Shu-cheongdschui@cuhk.edu.hk1[1], 0000"/>
 <result pre="this article, unless otherwise stated. Abstract Background Acute exacerbations of" exact="chronic obstructive pulmonary disease" post="(AECOPD) and asthma are associated with a variety of"/>
 <result pre="Background Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and" exact="asthma" post="are associated with a variety of precipitating factors including"/>
 <result pre="multiplex polymerase chain reaction of patients hospitalized with AECOPD and" exact="asthma" post="exacerbations. In addition, infective etiologies were assessed for association"/>
 <result pre="outcome of the patients. Methods Adults admitted with AECOPD and" exact="asthma" post="exacerbations between August 2016 and July 2017 were recruited."/>
 <result pre="Results Altogether 402 patients with AECOPD, 80 stable COPD, 100" exact="asthma" post="exacerbation and 21 stable asthma subjects were recruited. Among"/>
 <result pre="AECOPD, 80 stable COPD, 100 asthma exacerbation and 21 stable" exact="asthma" post="subjects were recruited. Among those admitted for AECOPD and"/>
 <result pre="asthma subjects were recruited. Among those admitted for AECOPD and" exact="asthma" post="exacerbations, 141(35.1%) and 45(45.0%) respectively had pathogens identified in"/>
 <result pre="identified in the NPA specimens. The commonest virus identified was" exact="influenza" post="A followed by HRV. HRV typing identified HRV-A and"/>
 <result pre="readmission rates and mortality except that identification of pathogens in" exact="asthma" post="exacerbation was associated with a lower rate of readmissions"/>
 <result pre="60â€‰days. Conclusions Many respiratory viruses were associated with AECOPD and" exact="asthma" post="exacerbation. HRV-A and HRV-C were the more common HRV"/>
 <result pre="of pathogens in NPA was associated with less readmissions for" exact="asthma" post="patients at 30 and 60â€‰days. Trial registration ClinicalTrials.gov NCT02866357."/>
 <result pre="Health Bureau, HKSAR Government 13140671 Summary at a glance For" exact="asthma" post="and COPD exacerbations, identification of pathogens in nasopharyngeal aspirate"/>
 <result pre="not affect clinical outcomes except that identification of pathogens in" exact="asthma" post="exacerbation was associated with a lower rate of readmissions"/>
 <result pre="between 22 and 60% in patients with AECOPD [6]. For" exact="asthma" post="exacerbation, a previous study from the United Kingdom found"/>
 <result pre="that upper respiratory viral infections were associated with 80â€&quot;85% of" exact="asthma" post="exacerbations in children aged 9â€&quot;11â€‰years [7]. There are limited"/>
 <result pre="9â€&quot;11â€‰years [7]. There are limited data on viral aetiologies for" exact="asthma" post="exacerbation in adults. A recent study in Australia found"/>
 <result pre="aetiologies were identified in 32, 5 and 7% respectively of" exact="asthma" post="exacerbations with hospital admissions [8]. HRVs are a major"/>
 <result pre="admissions [8]. HRVs are a major trigger of AECOPD and" exact="asthma" post="exacerbations and may pose a significant problem for disease"/>
 <result pre="respiratory viruses, HRV infection preceded as many as 50% of" exact="asthma" post="exacerbations in children [11]. Over 100 types of HRVs"/>
 <result pre="the subtypes of HRV that is related to adults with" exact="asthma" post="exacerbations [14]. Furthermore it is unknown that if certain"/>
 <result pre="the typing of HRV) in relation to acute exacerbations of" exact="asthma" post="and COPD. The secondary aim was to assess if"/>
 <result pre="hospitalization, 30 and 60-day readmissions and mortality. Methods Subjects with" exact="asthma" post="exacerbation or AECOPD who were admitted to the Prince"/>
 <result pre="for at least two consecutive days [16, 17]. Patients with" exact="asthma" post="exacerbations were subjects aged â‰¥18â€‰years, who had background asthma"/>
 <result pre="with asthma exacerbations were subjects aged â‰¥18â€‰years, who had background" exact="asthma" post="(with a consistent history, prior documented evidence of variable"/>
 <result pre="wheeze or cough for at least 2 consecutive days. Control" exact="asthma" post="and COPD subjects were recruited from the respiratory clinic"/>
 <result pre="of lung resection or other significant pulmonary diseases such as" exact="pulmonary fibrosis," post="active infection such as pulmonary tuberculosis and having short"/>
 <result pre="pulmonary diseases such as pulmonary fibrosis, active infection such as" exact="pulmonary tuberculosis" post="and having short life expectancies including subjects with terminal"/>
 <result pre="diseases such as pulmonary fibrosis, active infection such as pulmonary" exact="tuberculosis" post="and having short life expectancies including subjects with terminal"/>
 <result pre="from the patients within 1â€&quot;2â€‰days of hospitalization for exacerbation of" exact="asthma" post="and COPD. This study was approved by the Joint"/>
 <result pre="22 respiratory pathogens (coronavirus 229E, HKU1, NL63, OC43, human metapneumovirus," exact="influenza" post="A (including H1 and H3), influenza A H1N1pdm09, influenza"/>
 <result pre="NL63, OC43, human metapneumovirus, influenza A (including H1 and H3)," exact="influenza" post="A H1N1pdm09, influenza B, parainfluenza 1, 2, 3 &amp;amp;"/>
 <result pre="metapneumovirus, influenza A (including H1 and H3), influenza A H1N1pdm09," exact="influenza" post="B, parainfluenza 1, 2, 3 &amp;amp; 4, rhinovirus/enterovirus, RSV-A"/>
 <result pre="baseline assessment for up to 2â€‰months. For control COPD and" exact="asthma" post="patients, we identified patients from the out-patient clinic and"/>
 <result pre="aimed at recruiting 400 episodes of AECOPD, 100 episodes of" exact="asthma" post="exacerbation and 1/5 the number of exacerbation of subjects"/>
 <result pre="to the prevalence of different viruses found in AECOPD and" exact="asthma" post="patients and comparisons with the control subjects were done"/>
 <result pre="recruited 402 patients with AECOPD, 80 stable COPD, 100 with" exact="asthma" post="exacerbation, and 21 with stable asthma subjects for this"/>
 <result pre="stable COPD, 100 with asthma exacerbation, and 21 with stable" exact="asthma" post="subjects for this study. The characteristics of the COPD"/>
 <result pre="subjects for this study. The characteristics of the COPD and" exact="asthma" post="subjects are shown in TableÂ 1. The exacerbation and"/>
 <result pre="and inhaler therapies. Table 1 Characteristics of the COPD and" exact="asthma" post="patients Subjects with acute exacerbation of COPD (nÂ =â€‰402)"/>
 <result pre="(nÂ =â€‰80) p-value(compared acute exacerbation and stable COPD) Subjects with" exact="asthma" post="exacerbation of (nÂ =â€‰100) Control asthma (nÂ =â€‰21) p-value(compared"/>
 <result pre="stable COPD) Subjects with asthma exacerbation of (nÂ =â€‰100) Control" exact="asthma" post="(nÂ =â€‰21) p-value(compared acute and stable asthma) Gender (Male)"/>
 <result pre="(49.5%) 75 (93.8%) 30 (30.0%) 4 (19.0%) 0.23 Comorbidities â€ƒOld" exact="tuberculosis" post="67 (16.6%) 9 (11.3%) 0.22 4 (4.0%) 0 (0.0%)"/>
 <result pre="(8.9%) 4 (5.0%) 0.24 9 (9.0%) 0 (0.0%) 0.35 â€ƒIschaemic" exact="heart disease" post="38 (9.4%) 5 (6.2%) 0.35 7 (7.0%) 1 (4.7%)"/>
 <result pre="AdditionalÂ fileÂ 1: Figure S1. Only the AECOPD group and" exact="asthma" post="exacerbation group (not control subjects), had influenza A identified"/>
 <result pre="AECOPD group and asthma exacerbation group (not control subjects), had" exact="influenza" post="A identified by RTPCR in the NPA. For those"/>
 <result pre="by RTPCR in the NPA. For those with AECOPD and" exact="asthma" post="exacerbation subjects, 5 out of the 50 (10.0%) and"/>
 <result pre="had the H1N1pdm09 strain identified respectively. The rest of the" exact="influenza" post="A belonged to the H3N2 strain. Fig. 1 NPA"/>
 <result pre="with those without isolation of pathogens. Among 100 subjects with" exact="asthma" post="exacerbation, 45(45.0%) had pathogens detected. 5(5.0%) subjects had co-infections"/>
 <result pre="co-infections with more than 1 pathogen studied. Among the 21" exact="asthma" post="control subjects, only 1(4.8%) subject had parainfluenza virus detected."/>
 <result pre="had parainfluenza virus detected. The prevalence of microorganisms identified in" exact="asthma" post="(exacerbated asthma and stable) patients is shown in Fig.Â"/>
 <result pre="virus detected. The prevalence of microorganisms identified in asthma (exacerbated" exact="asthma" post="and stable) patients is shown in Fig.Â 2. The"/>
 <result pre="file 1: Figure S2. Fig. 2 NPA results of the" exact="asthma" post="cases. a: Patients with acute exacerbation of asthma and"/>
 <result pre="of the asthma cases. a: Patients with acute exacerbation of" exact="asthma" post="and stable asthma with or without microorganisms detected in"/>
 <result pre="cases. a: Patients with acute exacerbation of asthma and stable" exact="asthma" post="with or without microorganisms detected in the NPA. b:"/>
 <result pre="M pneumoniaeâ€‰=â€‰Mycoplasma pneumoniae; HRVsâ€‰=â€‰Human rhinovirus; RSVâ€‰=â€‰Respiratory syncytial virus Subjects with" exact="asthma" post="exacerbations with detection of pathogens in the NPA had"/>
 <result pre="in the NPA vs those without microorganisms identified for both" exact="asthma" post="and COPD exacerbations. Results are shown in TableÂ 2."/>
 <result pre="unit, NIV non-invasive ventilation Comparison of subjects with and without" exact="influenza" post="vaccination found that the rate of influenza-related exacerbations appeared"/>
 <result pre="of influenza-related exacerbations appeared to be higher in those with" exact="influenza" post="vaccination but that did not reach statistical significance. Results"/>
 <result pre="shown in TableÂ 3. Table 3 Subjects with and without" exact="influenza" post="vaccination and rate of admission for exacerbations with influenza"/>
 <result pre="without influenza vaccination and rate of admission for exacerbations with" exact="influenza" post="A or B isolated in the NPA among subjects"/>
 <result pre="B isolated in the NPA among subjects with COPD and" exact="asthma" post="AECOPD (nÂ =â€‰402) Asthma exacerbation (nÂ =â€‰100) With flu"/>
 <result pre="B identified in NPA among the subjects with or without" exact="influenza" post="vaccination in the COPD* and asthma# acute exacerbation subjects:*pÂ"/>
 <result pre="detected in 26, 11 and 1 subjects respectively with AECOPD," exact="asthma" post="exacerbations and stable COPD. No subject in stable asthma"/>
 <result pre="AECOPD, asthma exacerbations and stable COPD. No subject in stable" exact="asthma" post="group had HRV identified in the NPA. The subtypes"/>
 <result pre="identified in the subjects AECOPD Stable COPD Asthma exacerbation Stable" exact="asthma" post="HRV_A HRV_A1 HRV_A7 HRV_A21 HRV_A33 HRV_A33 HRV_A36 HRV_A36 HRV_A43"/>
 <result pre="between the various types of HRV in both AECOPD and" exact="asthma" post="exacerbations with hospital LOS, readmission and mortality. The results"/>
 <result pre="relationships of HRV types and clinical outcomes of AECOPD and" exact="asthma" post="exacerbation are shown in Additional file 1: Tables S1"/>
 <result pre="detection of respiratory pathogens of adults hospitalized for AECOPD and" exact="asthma" post="exacerbations, this study has found that the rates of"/>
 <result pre="rates were much lower among the corresponding control COPD and" exact="asthma" post="subjects, which were 11.2 and 4.8% respectively. HRV typing"/>
 <result pre="the more common HRV that were associated with AECOPD and" exact="asthma" post="exacerbations with a wide variety of genotypes. Detection of"/>
 <result pre="the hospital LOS, readmissions and mortality except that patients with" exact="asthma" post="exacerbation, identification of pathogens was associated with a lower"/>
 <result pre="our previous study 10â€‰years ago (35.1 vs 22%) [1], and" exact="influenza" post="A viruses remained the most common pathogen identified. Most"/>
 <result pre="commonest virus identified [6]. In contrast, relatively few studies reported" exact="influenza" post="A as the most frequently found virus [20, 21]."/>
 <result pre="as the most frequently found virus [20, 21]. Among the" exact="asthma" post="subjects, 45.0% had pathogens detected in this study. Most"/>
 <result pre="of the previous studies on detection of respiratory pathogens in" exact="asthma" post="exacerbations were conducted in children [22]. A Korean study"/>
 <result pre="in children [22]. A Korean study found that in adult" exact="asthma" post="subjects with acute exacerbation, 26.3% had viruses identified in"/>
 <result pre="HRV being the commonest organisms identified [24]. Adult subjects with" exact="asthma" post="exacerbation thus appeared to have a lower rate of"/>
 <result pre="identified in the NPA were observed in this study with" exact="influenza" post="viruses reaching the peak in November to February and"/>
 <result pre="July for AECOPD. A similar pattern was observed for adult" exact="asthma" post="exacerbation with influenza virus detection which peaked in November"/>
 <result pre="A similar pattern was observed for adult asthma exacerbation with" exact="influenza" post="virus detection which peaked in November and June to"/>
 <result pre="June to July. This pattern was in phase with the" exact="influenza" post="seasonal patterns in Hong Kong [25]. A study of"/>
 <result pre="of airway diseases in the UK were related to childhood" exact="asthma" post="with a seasonal increase of HRV infections in September"/>
 <result pre="Spring [26]. Similar patterns were noted for adult COPD and" exact="asthma" post="exacerbation patients in this study. For children, HRV-A and"/>
 <result pre="For children, HRV-A and HRV-C are more frequently associated with" exact="asthma" post="exacerbations. A cross-sectional study of subjects aged 13]. Similar"/>
 <result pre="A cross-sectional study of subjects aged 13]. Similar observation for" exact="asthma" post="children in other parts of the world was observed"/>
 <result pre="those requiring hospitalization [30, 31]. In contrast, our adults with" exact="asthma" post="exacerbation had HRV-A being isolated from the NPA more"/>
 <result pre="that HRV-A or HRV-C had a potential role in precipitating" exact="asthma" post="attacks among Japanese adult patients, with a broad genetic"/>
 <result pre="generally have not typed the HRV. Those with history of" exact="influenza" post="vaccination appeared to have a higher rate of identification"/>
 <result pre="vaccination appeared to have a higher rate of identification of" exact="influenza" post="viruses in the NPA than those without vaccination for"/>
 <result pre="the NPA than those without vaccination for both AECOPD and" exact="asthma" post="exacerbation though this did not reach statistical significance. A"/>
 <result pre="suggested that protective serum antibody titres in COPD patients after" exact="influenza" post="vaccination was lower than control subjects [32]. Overall the"/>
 <result pre="lower than control subjects [32]. Overall the mortality benefit of" exact="influenza" post="vaccine in COPD is suggested by some studies but"/>
 <result pre="Another systemic review indicated a favorable benefit-risk ratio for seasonal" exact="influenza" post="vaccination in patients with COPD [34]. For persons with"/>
 <result pre="For persons with asthma, a recent systematic review observed that" exact="influenza" post="vaccination might be effective in both reducing influenza infection"/>
 <result pre="observed that influenza vaccination might be effective in both reducing" exact="influenza" post="infection and asthma attacks [35]. However, another Cochrane review"/>
 <result pre="vaccination might be effective in both reducing influenza infection and" exact="asthma" post="attacks [35]. However, another Cochrane review has expressed uncertainty"/>
 <result pre="review has expressed uncertainty of the degree of protection that" exact="influenza" post="vaccination might confer against asthma exacerbations that are related"/>
 <result pre="the degree of protection that influenza vaccination might confer against" exact="asthma" post="exacerbations that are related to influenza infection [36]. During"/>
 <result pre="vaccination might confer against asthma exacerbations that are related to" exact="influenza" post="infection [36]. During the study period from August 2016"/>
 <result pre="During the study period from August 2016 to July 2017," exact="influenza" post="A(H3N2) was the main circulating strain causing the Summer"/>
 <result pre="sites and distances in addition to egg adaptation especially for" exact="influenza" post="A(H3N2) virus [38]. A previous systematic review found substantial"/>
 <result pre="virus [38]. A previous systematic review found substantial variations in" exact="influenza" post="vaccine effectiveness across types and subtypes of influenza with"/>
 <result pre="variations in influenza vaccine effectiveness across types and subtypes of" exact="influenza" post="with substantially lower protection against H3N2 [39]. Examination of"/>
 <result pre="influenza with substantially lower protection against H3N2 [39]. Examination of" exact="influenza" post="vaccine effectiveness by serology is beyond the scope of"/>
 <result pre="due to current or previous infection or vaccination by measuring" exact="influenza" post="antibody based on haemagglutinin inhibition. While identification of pathogens"/>
 <result pre="lower rate of readmissions for asthma, exacerbations of COPD and" exact="asthma" post="might also be due to other acute and transient"/>
 <result pre="were other factors that might be associated with AECOPD and" exact="asthma" post="exacerbations, e.g. air pollution, weather changes, allergic sensitization, etc."/>
 <result pre="viral and atypical pathogens that were associated with AECOPD and" exact="asthma" post="exacerbations in hospitalized patients. HRV typing suggested that HRV-A"/>
 <result pre="more common HRV subtypes that were associated with AECOPD and" exact="asthma" post="exacerbations with a wide variety of genotypes. Presence of"/>
 <result pre="mortality except that patients who had infective aetiology identified during" exact="asthma" post="exacerbation had lower rates of readmissions at 30 and"/>
 <result pre="cases in different months. Figure S2. NPA results of the" exact="asthma" post="exacerbation cases in different months. (DOCX 145 kb) Abbreviations"/>
 <result pre="competing interests. References References 1.KoFWIpMChanPKChanMCChanMCToKWNgSSChauSSTangJWHuiDSViral etiology of acute exacerbations of" exact="chronic obstructive pulmonary disease" post="in Hong KongChest200713290090810.1378/chest.07-053017573516 2.KoFWIpMChanPKFokJPChanMCNgaiJCChanDPHuiDSA 1-year prospective study of the"/>
 <result pre="2018). 4.KoFWTamWWongTWChanDPTungAHLaiCKHuiDSTemporal relationship between air pollutants and hospital admissions for" exact="chronic obstructive pulmonary disease" post="in Hong KongThorax20076278078510.1136/thx.2006.07616617311838 5.KoFWTamWWongTWLaiCKWongGWLeungTFNgSSHuiDSEffects of air pollution on asthma"/>
 <result pre="pulmonary disease in Hong KongThorax20076278078510.1136/thx.2006.07616617311838 5.KoFWTamWWongTWLaiCKWongGWLeungTFNgSSHuiDSEffects of air pollution on" exact="asthma" post="hospitalization rates in different age groups in Hong KongClin"/>
 <result pre="al.Community study of role of viral infections in exacerbations of" exact="asthma" post="in 9-11 year old childrenBMJ19953101225122910.1136/bmj.310.6989.12257767192 8.WarkPAToozeMPowellHParsonsKViral and bacterial infection"/>
 <result pre="9-11 year old childrenBMJ19953101225122910.1136/bmj.310.6989.12257767192 8.WarkPAToozeMPowellHParsonsKViral and bacterial infection in acute" exact="asthma" post="and chronic obstructive pulmonary disease increases the risk of"/>
 <result pre="old childrenBMJ19953101225122910.1136/bmj.310.6989.12257767192 8.WarkPAToozeMPowellHParsonsKViral and bacterial infection in acute asthma and" exact="chronic obstructive pulmonary disease" post="increases the risk of readmissionRespirology201318996100210.1111/resp.1209923600594 9.JohnstonNWJohnstonSLDuncanJMGreeneJMKebadzeTKeithPKRoyMWasermanSSearsMRThe September epidemic of"/>
 <result pre="disease increases the risk of readmissionRespirology201318996100210.1111/resp.1209923600594 9.JohnstonNWJohnstonSLDuncanJMGreeneJMKebadzeTKeithPKRoyMWasermanSSearsMRThe September epidemic of" exact="asthma" post="exacerbations in children: a search for etiologyJ Allergy Clin"/>
 <result pre="J20001667768310.1034/j.1399-3003.2000.16d19.x11106212 11.ThumerelleCDeschildreABouquillonCSantosCSardetAScalbertMDelbecqueLDebrayPDewildeATurckDLeclercFRole of viruses and atypical bacteria in exacerbations of" exact="asthma" post="in hospitalized children: a prospective study in the Nord-pas"/>
 <result pre="in the development of therapeutic agents for viral exacerbations of" exact="asthma" post="and chronic obstructive pulmonary diseasePulm Pharmacol Ther201430C3243 13.MakRKTseLYLamWYWongGWChanPKLeungTFClinical spectrum"/>
 <result pre="14.JarttiTGernJERole of viral infections in the development and exacerbation of" exact="asthma" post="in childrenJ Allergy Clin Immunol201714089590610.1016/j.jaci.2017.08.00328987219 15.Global Initiative for Chronic"/>
 <result pre="Strategy for the diagnosis, management, and prevention of chronic obstructive" exact="lung disease." post="Updated 2018. 2018:http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf (last assessed date 20 Feb 2018)."/>
 <result pre="To MYYeungACWongYSWongGWChanPKMultiplex molecular detection of respiratory pathogens in children with" exact="asthma" post="exacerbationChest201013734835410.1378/chest.09-125019749009 25.Center for Health Protection. Department of Health. The"/>
 <result pre="Erbas B. The role of human rhinovirus (HRV) species on" exact="asthma" post="exacerbation severity in children and adolescents. The Journal of"/>
 <result pre="asthma exacerbation severity in children and adolescents. The Journal of" exact="asthma" post=": official journal of the Association for the Care"/>
 <result pre="SpainPediatr Infect Dis J20102971772010.1097/INF.0b013e3181d7a70820305581 29.KhetsurianiNLuXTeagueWGKazerouniNAndersonLJErdmanDDNovel human rhinoviruses and exacerbation of" exact="asthma" post="in childrenEmerg Infect Dis2008141793179610.3201/eid1411.08038618976575 30.CoxDWBizzintinoJFerrariGKhooSKZhangGWhelanSLeeWMBochkovYAGeelhoedGCGoldblattJGernJELaingIALe SouefPNHuman rhinovirus species C"/>
 <result pre="on viral replication and cytokine productionJ Allergy Clin Immunol201413433234110.1016/j.jaci.2014.01.02924636084 32.EaganTMHardieJAJul-LarsenAGrydelandTBBakkePSCoxRJSelf-reported" exact="influenza" post="vaccination and protective serum antibody titers in a cohort"/>
 <result pre="understanding immunogenicity, efficacy and effectivenessTher Adv Respir Dis20161034936710.1177/175346581664605027193567 34.Bekkat-BerkaniRWilkinsonTBuchyPDos SantosGStefanidisDDevasterJMMeyerNSeasonal" exact="influenza" post="vaccination in patients with COPD: a systematic literature reviewBMC"/>
 <result pre="a systematic literature reviewBMC pulmonary medicine2017177910.1186/s12890-017-0420-828468650 35.VasileiouESheikhAButlerCEl FerkhKvon WissmannBMcMenaminJRitchieLSchwarzeJPapadopoulosNGJohnstonSLTianLSimpsonCREffectiveness of" exact="influenza" post="vaccines in asthma: a systematic review and meta-analysisClinical infectious"/>
 <result pre="Society of America2017651388139510.1093/cid/cix52428591866 36.Cates CJ, Rowe BH. Vaccines for preventing" exact="influenza" post="in people with asthma. The Cochrane database of systematic"/>
 <result pre="(Last access date 24 Aug 2018). 2018;15:1â€&quot;7. 38.ZostSJParkhouseKGuminaMEKimKDiaz PerezSWilsonPCTreanorJJSantAJCobeySHensleySEContemporary H3N2" exact="influenza" post="viruses have a glycosylation site that alters binding of"/>
 <result pre="egg-adapted vaccine strainsProc Natl Acad Sci U S A2017114125781258310.1073/pnas.171237711429109276 39.BelongiaEASimpsonMDKingJPSundaramMEKelleyNSOsterholmMTMcLeanHQVariable" exact="influenza" post="vaccine effectiveness by subtype: a systematic review and meta-analysis"/>
</results>
